Priveterra Acquisition Corp. (NASDAQ:PMGM) announced in an 8-K this afternoon that it will adjourn its special meeting to approve its combination with AEON Biopharma from noon today to the same time on June 21, marking the fourth adjournment for the meeting.
On June 13, the SPAC received a notice from The Nasdaq advising the company that for the last 30 consecutive business days, its market value of listed securities has been below the minimum of $35 million required for continued listing.
Priveterra’s securities will continue to trade on the Nasdaq, but it now has 180 calendar days, or until December 11, to regain compliance. In order to do so, PMGM must trade at or above a level such that its market value closes at or above $35 million for a minimum of ten consecutive business days. If the company fails to do this, then it will face a delisting. Privettera intends to monitor its market value and may consider implementing available options to regain its compliance.
The SPAC continues to state that it has been using this additional time during the postponement to further engage with its shareholders. Aside from voting on a proposal to approve the business combination, shareholders are also voting on proposals pertaining to the management’s powers to make certain governance changes and allowing the company to issue up to 39,913,926 upon close to comply with listing requirements.
Priveterra’s deal with AEON Biopharma includes a $40 million minimum cash condition, half of which has already been secured through a $20 million commitment from existing AEON investors at $7 per share.
But, the SPAC’s trust, originally totaling $276 million, has been reduced to about $20.3 million after seeing 92.7% of shares redeemed in earlier votes. It now has until August 11 to close the deal.
Priveterra inked its $201.8 million business combination with drug developer AEON on December 13. Irvine, California-based AEON is working on an injection-based migraine treatment to compete with Botox for chronic and frequent sufferers.
Colombier Acquisition Corp. II (NYSE: CLBR.U) announced the pricing of its upsized $150 million IPO this evening. Its units are expected to begin trading on the NYSE under the symbol “CLBR.U” on Tuesday, November 21, 2023. After the securities comprising the units begin separate trading, the Class A ordinary shares and rights are expected to...
Mountain Crest Acquisition Corp. IV (NASDAQ:MCAF) announced this afternoon that its shareholders have approved its business combination with CH-AUTO. At today’s meeting, there were 2,958,185 shares of common stock present, representing approximately 89.25% of the issued and outstanding shares, constituting a quorum. The deal was approved with holders of 2,704,338 shares voting in favor of...
Bayview Acquisition Corp. (NASDAQ:BAYA) submitted its S-1 filing Friday afternoon for a $50 million IPO with a primary focus on businesses in Asia. The new SPAC states that it sees Asia transitioning into a new phase of economic development, foreseeing promising opportunities for a business combination. They anticipate this growth to stem from private sector...
Plenty of stocks are rebounding this month as the market broadly rallies on signs that the age of rate hikes is ending, but DraftKings (NASDAQ:DKNG) is on an uncommonly sharp trajectory among recent de-SPACs. The digital gaming and betting platform, which combined with Diamond Eagle in April 2020, opened 2023 trading at $11.63 – nearly...
At the SPAC of Dawn Public companies of all stripes tend to bury news ahead of holidays and SPACs are no different. Four SPACs have announced their intent to liquidate since market close on Friday and three of these had previously agreed to business combinations. The last cluster of broken deals and liquidated SPACs this...